Showing 11-14 of 14 results for "".
- CSF Kicks Off in Nashvillehttps://practicaldermatology.com/news/csf-kicks-off-in-nashville/2460229/Cosmetic Surgery Forum (CSF), now in its 11th year, has kicked off in Nashville. It’s the meeting’s first time in the Music City, which allows for live injection sessions—a popular meeting highlight. The program covers everything from cannabidiol (CBD) in skincare and platelet-rich plasma (PRP) for…
- Topical PDE4 Inhibitor from Arcutis Shows Benefit in Seborrheic Dermatitishttps://practicaldermatology.com/news/topical-pde4-inhibitor-from-arcutis-shows-benefit-in-seborrheic-dermatitis/2460544/Positive topline data from a Phase 2 clinical trial suggest ARQ-154 (topical roflumilast foam) from Arcutis Biotherapeutics, Inc. is a potential treatment for seborrheic dermatitis. Study results show that roflumilast foam 0.3% administered once daily for eight weeks demonstrated statistically sig…
- Arcutis Moves Another Candidate Into Phase 3 Trialshttps://practicaldermatology.com/news/arcutis-moves-another-candidate-into-phase-3-trials/2460664/Roughly a week after announcing plans to initiate Phase 3 clinical trials for topical roflumilast cream (ARQ-151) in the treatment of atopic dermatitis (AD), Arcutis Biotherapeutics, Inc. is now doing the same for topical roflumilast foam (ARQ-154) for seborrheic dermatitis following an End-of-Pha…
- Dermavant to Present New ADORING Data from Phase 3 Trials of Vtama Cream for AD at 2024 AAD Annual Meetinghttps://practicaldermatology.com/news/dermavant-to-present-new-adoring-data-from-phase-3-trials-of-vtama-cream-for-ad-at-2024-aad-annual-meeting/2462258/Dermavant Sciences announced that new ADORING data, including treatment of patients with skin of color, from phase 3 trials of Vtama (tapinarof) cream 1% in adults and children 2 years of age and older with atopic dermatitis (AD), will be presented at the 2024 American Academy of Dermatology annual…
- Previous
- Next